| CASE REPORT |
|
| Year : 2018 | Volume
: 1
| Issue : 4 | Page : 142-144 |
|
|
Development of drug-induced arthritis in a glioblastoma patient treated with pembrolizumab
Casey B Brown, Katherine B Peters
Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA
Correspondence Address:
Dr. Katherine B Peters
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, PO Box 3624, Durham, NC 27710
USA
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/glioma.glioma_28_18
|
|
|
Glioblastoma (GBM, WHO Grade IV) is the most aggressive form of primary brain cancer in adults, and as with other cancers, clinical investigations to use immunotherapy as a possible therapeutic option for GBM are underway. One form of immunotherapy is immune checkpoint inhibition that targets the programmed cell death-1 (PD-1) receptor on lymphocytes. While PD-1 receptor inhibitors, such as pembrolizumab, are often tolerable, there can be dose-limiting immune-related adverse effects, which have the potential to result in impaired health-related quality of life. This case report discusses one patient with recurrent GBM who received pembrolizumab and developed refractory drug-induced arthritis.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
